Human ES-derived cardiomyocytes regenerate non-human primate hearts

ceazon

! D' B* s& ^4 o% o7 U
9 B) |6 m) Y  T9 L. w& N

5 d  _8 d# Y! j* V) ~( U3 f! e! Y
' p2 y5 M4 G; KHuman embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts
% K& Y" c$ N- |! R2 q, I
1 F3 X3 ^- t8 d$ r: U ! U- Q: F6 U" s  K" Y
6 r  P2 W7 P2 a# m0 k
Pluripotent stem cells provide a potential solution to current epidemic rates of heart failure1 by providing human cardiomyocytes to support heart regeneration2. Studies of human embryonic-stem-cell-derived cardiomyocytes (hESC-CMs) in small-animal models have shown favourable effects of this treatment. However, it remains unknown whether clinical-scale hESC-CM transplantation is feasible, safe or can provide sufficient myocardial regeneration. Here we show that hESC-CMs can be produced at a clinical scale (more than one billion cells per batch) and cryopreserved with good viability. Using a non-human primate model of myocardial ischaemia followed by reperfusion, we show that that cryopreservation and intra-myocardial delivery of one billion hESC-CMs generates extensive remuscularization of the infarcted heart. The hESC-CMs showed progressive but incomplete maturation over a 3-month period. Grafts were perfused by host vasculature, and electromechanical junctions between graft and host myocytes were present within 2 weeks of engraftment. Importantly, grafts showed regular calcium transients that were synchronized to the host electrocardiogram, indicating electromechanical coupling. In contrast to small-animal models7, non-fatal ventricular arrhythmias were observed in hESC-CM-engrafted primates. Thus, hESC-CMs can remuscularize substantial amounts of the infarcted monkey heart. Comparable remuscularization of a human heart should be possible, but potential arrhythmic complications need to be overcome.

bubble_w

求原文

cortex

原文